儿童期预测因素与肺功能轨迹及未来慢阻肺风险:从幼年至第六个十年的前瞻性队列研究
该研究基于塔斯马尼亚纵向健康研究(TAHS)六个时间点(7、13、18、45、50、53岁)的支气管扩张前FEV1 z评分,用基于组的轨迹模型识别出6条肺功能轨迹。其中三条轨迹(早期低于平均并加速下降、持续低、低于平均)在53岁时慢阻肺风险显著升高,且与儿童期哮喘、支气管炎、肺炎、过敏性鼻炎、湿疹、父母哮喘及母亲吸烟等可干预因素相关。
要点
- 儿童期肺功能轨迹可分6类,其中3类贡献约75%的慢阻肺负担。
- 儿童期哮喘、母亲吸烟等可干预因素与不良轨迹相关,成人因素可加剧其影响。
核心结论
- 研究识别出6条潜在FEV1轨迹,其中两条为新发现。
- 三条轨迹贡献约75%的慢阻肺负担,并与可干预的早期暴露相关。
- 减少母亲吸烟、鼓励免疫接种、避免个人吸烟或可降低慢阻肺风险。
- 临床医生与哮喘患者应知晓哮喘控制不佳对终生肺功能的潜在长期影响。
研究设计与样本
- 采用塔斯马尼亚纵向健康研究(TAHS)六个波次数据,对7、13、18、45、50、53岁测量的支气管扩张前FEV1 z评分进行基于组的轨迹建模。
- 原始队列8583名参与者中,2438名在7岁与53岁至少有两个波次肺功能数据并构成研究人群。
- 采用logistic回归分析轨迹与儿童期因素及慢阻肺风险的关联,并估计慢阻肺的人群归因分数。
主要发现
- 识别出6条轨迹:早期低于平均并加速下降(97例,4%)、持续低(136例,6%)、早期低并加速增长后正常下降(196例,8%)、持续高(293例,12%)、低于平均(772例,32%)、平均(944例,39%)。
- 三条轨迹的早期预测因素包括儿童期哮喘、支气管炎、肺炎、过敏性鼻炎、湿疹、父母哮喘及母亲吸烟。
- 个人吸烟与成人活动性哮喘分别加剧母亲吸烟与儿童期哮喘对早期低于平均并加速下降轨迹的影响。
临床怎么用
- 对儿童期哮喘、支气管炎、肺炎、过敏性鼻炎、湿疹、父母哮喘或母亲吸烟者,应关注其肺功能轨迹并早期干预。
- 建议减少母亲吸烟、鼓励免疫接种、避免个人吸烟,尤其针对吸烟父母或儿童期肺功能偏低者。
- 对哮喘患者应强调优化哮喘控制对终生肺功能的潜在益处。
局限性
- 研究基于塔斯马尼亚纵向健康研究队列,外部推广性需谨慎。
- 轨迹模型基于支气管扩张前FEV1 z评分,未涵盖其他肺功能指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lifetime lung function is related to quality of life and longevity. Over the lifespan, individuals follow different lung function trajectories. Identification of these trajectories, their determinants, and outcomes is important, but no study has done this beyond the fourth decade. METHODS: We used six waves of the Tasmanian Longitudinal Health Study (TAHS) to model lung function trajectories measured at 7, 13, 18, 45, 50, and 53 years. We analysed pre-bronchodilator FEV1 z-scores at the six timepoints using group-based trajectory modelling to identify distinct subgroups of individuals whose measurements followed a similar pattern over time. We related the trajectories identified to childhood factors and risk of chronic obstructive pulmonary disease (COPD) using logistic regression, and estimated population-attributable fractions of COPD. FINDINGS: Of the 8583 participants in the original cohort, 2438 had at least two waves of lung function data at age 7 years and 53 years and comprised the study population. We identified six trajectories: early below average, accelerated decline (97 [4%] participants); persistently low (136 [6%] participants); early low, accelerated growth, normal decline (196 [8%] participants); persistently high (293 [12%] participants); below average (772 [32%] participants); and average (944 [39%] participants). The three trajectories early below average, accelerated decline; persistently low; and below average had increased risk of COPD at age 53 years compared with the average group (early below average, accelerated decline: odds ratio 35·0, 95% CI 19·5-64·0; persistently low: 9·5, 4·5-20·6; and below average: 3·7, 1·9-6·9). Early-life predictors of the three trajectories included childhood asthma, bronchitis, pneumonia, allergic rhinitis, eczema, parental asthma, and maternal smoking. Personal smoking and active adult asthma increased the impact of maternal smoking and childhood asthma, respectively, on the early below average, accelerated decline trajectory. INTERPRETATION: We identified six potential FEV1 trajectories, two of which were novel. Three trajectories contributed 75% of COPD burden and were associated with modifiable early-life exposures whose impact was aggravated by adult factors. We postulate that reducing maternal smoking, encouraging immunisation, and avoiding personal smoking, especially in those with smoking parents or low childhood lung function, might minimise COPD risk. Clinicians and patients with asthma should be made aware of the potential long-term implications of non-optimal asthma control for lung function trajectory throughout life, and the role and benefit of optimal asthma control on improving lung function should be investigated in future intervention trials. FUNDING: National Health and Medical Research Council of Australia; European Union's Horizon 2020; The University of Melbourne; Clifford Craig Medical Research Trust of Tasmania; The Victorian, Queensland & Tasmanian Asthma Foundations; The Royal Hobart Hospital; Helen MacPherson Smith Trust; and GlaxoSmithKline.
引用
- Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med. 2018. PMID: 29628376. doi:10.1016/S2213-2600(18)30100-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。